Sign in
Taking peoplePhase 2

Naturally Produced Cannabinoids for Neuroprotection From Concussion

Key facts

Who runs it
University of Regina
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
1 Jun 2026
Expected to end
Mar 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Broad spectrum cannabinoid formulation
  • Placebo gel capsule
Record updated
21 July 2026

Who can take part

Age
19 years to 35 years
Sex
Men only
Healthy volunteers
Can take part
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Healthy male adults between 19-35 years of age that compete in contact sport athletics
  • Participants with no known cerebrovascular or cardiovascular complications
  • Participants will not be habitual recreational users of cannabis (i.e., <1 day/week) or tobacco users
  • Participants that agree not use any other cannabis or tobacco products while enrolled in the study
  • Participants willing to provide a list of any prescription medications they are taking
  • Ability to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, perceptual-cognitive, and functional motor skills laboratory tests
  • Participants who are capable of giving signed informed consent

Who cannot take part

  • Use of cannabis-based therapy within 2 months (participants who have previously used a cannabis based therapy may be included if they have a 2-month period without use of cannabis-based therapy prior to enrollment in the study)
  • Participants who are taking prescription medications such as psychotropic medications with serotonergic activity, including Selective Serotonin Reuptake Inhibitors (i.e. Fluoxetine), Tricyclic Antidepressants (i.e. Elavil, Nortriptyline) and Atypical Neuroleptics (i.e. Risperidone, Seroquel)
  • Initiation or dosage change of oral or injected steroids within 3 months
  • Participants that are being medically supervised for anxiety, depression, Post Traumatic Stress Disorder (PTSD), mood disorder, psychotic disorders or any cerebrovascular and cardiovascular complications
  • Allergy or known intolerance to any of the compounds within the study preparation
  • Inability of study participants to attend assessments on a regular basis at the pre-determined times, or failure to take the drug daily
  • Clinically significant cardiac, renal or hepatic disease (as assessed by the site investigator)
  • Unable to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, and functional motor skills laboratory tests
  • Female
  • Must not travel to the USA during study period; USA laws do not permit cross border with cannabis products
  • Participants with any level of cannabis in their blood samples when sampled at the commencement of the study will be excluded
  • If they already have a concussion at the time of starting the study

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex

This trial is currently available in Canada.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this double-blind, placebo-controlled, cross over study is to learn about the neuroprotective properties of a broad-spectrum cannabinoid formulation in normal healthy adults engaged in elite contact sport competition.

Read full original descriptionShow less

The main question it aims to answer :

• Is the broad-spectrum cannabinoid formulation neuroprotective for athletes participating in competitive contact sports? Can this formulation facilitate recovery in those who suffer from concussion by reducing inflammation and/or reduce the number of concussions sustained without adverse physiological and psychological dysfunction when administered daily?

Participants will:

* be given a broad-spectrum cannabinoid gel capsule or a placebo twice daily. * have blood samples taken to analyze pharmacokinetics and pharmacodynamics of cannabinoid metabolites, liver function, complete blood count and blood differential, inflammatory biomarkers and genetic analysis * have stool samples collected for gut microbiome analysis; * undergo testing sessions, which will include psychological and health questionnaires, equipment to record signals from the brain and heart, and safety laboratory tests.

The 2 groups in the trial

  • Broad sprectrum cannabinoid gel capsuleTreatment being tested

    Gel capsule containing broad spectrum cannabinoid formulation

    Treatment: Broad spectrum cannabinoid formulation

  • PlaceboPlacebo, for comparison

    Placebo gel capsule

    Treatment: Placebo gel capsule

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Naturally Produced Cannabinoids for Pain Management and Neuroprotection From Concussion During Participation in Contact Sports: Neuroprotection
Criteria questions
Built from NCT07715864, who can take part
Record updated
21 July 2026